APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

PURPOSE: Oliceridine is a novel G protein-biased µ-opioid receptor agonist designed to provide intravenous (IV) analgesia with a lower risk of opioid-related adverse events (ORAEs) than conventional opioids. PATIENTS AND METHODS: APOLLO-1 (NCT02815709) was a phase III, double-blind, randomized trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Viscusi, Eugene R, Skobieranda, Franck, Soergel, David G, Cook, Emily, Burt, David A, Singla, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417853/
https://www.ncbi.nlm.nih.gov/pubmed/30881102
http://dx.doi.org/10.2147/JPR.S171013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417853/
https://www.ncbi.nlm.nih.gov/pubmed/30881102
http://dx.doi.org/10.2147/JPR.S171013

Ejemplares similares